Stocktoria
PTC THERAPEUTICS, INC. PTCT
PTC THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B | $806.8M | $937.8M | $698.8M | $538.6M | $380.8M | $307.0M | $264.7M | $194.4M | $82.7M |
| R&D expense | $455.2M | $534.5M | $666.6M | $651.5M | $540.7M | $477.6M | $257.5M | $172.0M | $117.5M | $117.6M |
| SG&A expense | $347.1M | $300.9M | $332.5M | $326.0M | $285.8M | $245.2M | $202.5M | $153.5M | $121.3M | $97.1M |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$447.4M | -$374.4M | -$431.8M | -$241.2M | -$115.7M | -$64.3M | -$132.1M |
| Income tax | $14.0M | $176,000 | -$69.5M | -$28.5M | $5.6M | $35.2M | $11.7M | -$29,000 | $1.3M | $569,000 |
| Net income | $682.6M | -$363.3M | -$626.6M | -$559.0M | -$523.9M | -$438.2M | -$251.6M | -$128.1M | -$79.0M | -$142.1M |
| EPS (diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | — | — | — |
| Operating cash flow | $711.2M | -$107.7M | -$158.4M | -$356.7M | -$251.3M | -$194.1M | -$98.6M | -$27.6M | -$10.1M | -$103.6M |
| Free cash flow | $702.3M | -$114.2M | -$186.9M | -$388.7M | -$279.5M | -$211.9M | -$112.4M | -$34.7M | -$13.2M | -$105.3M |
| Cash & equivalents | $984.6M | $779.7M | $594.0M | $279.8M | $189.7M | $208.8M | $288.0M | $169.5M | $111.8M | $58.3M |
| Inventory | $79.6M | $23.2M | $30.6M | $21.8M | $15.9M | $18.7M | $19.3M | $16.1M | $10.8M | $0 |
| Total assets | $2.9B | $1.7B | $1.9B | $1.7B | $1.9B | $2.2B | $1.6B | $1.1B | $391.7M | $269.3M |
| Total liabilities | $3.1B | $2.8B | $2.7B | $2.1B | $1.9B | $1.7B | $1.0B | $768.5M | $235.2M | $149.8M |
| Shareholders' equity | -$205.3M | -$1.1B | -$818.6M | -$347.1M | $1.4M | $482.0M | $594.3M | $350.7M | $156.4M | $119.6M |
Growth · year-over-year · Revenue CAGR 40.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +114.5% | -14.0% | +34.2% | +29.7% | +41.4% | +24.0% | +16.0% | +36.2% | +135.0% | +124.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.